

STEVE BESHEAR
GOVERNOR



ROBERT D. VANCE
SECRETARY

PUBLIC PROTECTION CABINET

ROBERT M. BECK, JR.
CHAIRMAN

KENTUCKY HORSE RACING COMMISSION

LISA E. UNDERWOOD, EXECUTIVE DIRECTOR
4063 IRONWORKS PKWY, BLDG. B
LEXINGTON, KENTUCKY 40511
TELEPHONE: (859) 246-2040 FAX: (859) 246-2039
WEB SITE: WWW.KHRC.KY.GOV

FOR IMMEDIATE RELEASE

Contact: Dick Brown
(502) 564-5525

The Rules Committee and the Equine Drug Research Council of the Kentucky Horse Racing Commission will meet Tuesday Aug. 2, 2011 at the Kentucky Horse Racing Commission offices in Lexington. The respective times and agendas follow:

Rules Committee

Location: Offices of the Kentucky Horse Racing Commission
4063 Iron Works Parkway, Building B
Lexington, KY.
Tuesday Aug. 2, 2011
Time: 10 a.m. EDT

Agenda

- I. Call to order, roll call
- II. Amendments to 810 KAR 1:090 KY Thoroughbred Development Fund
- III. Amendments to 810 KAR 1:018; 811 KAR 1:090; 811 KAR 2:096 Medications, Testing Procedures, and Prohibited Practices
- IV. Amendments to 810 KAR 1:028; 811 KAR 1:095; 811 KAR 2:100 Disciplinary Measures and Penalties
- V. 810 KAR 1:040; 811 KAR 1:093; 811 KAR 2:093. Drug and Medication Classification Schedules and Withdrawal Guidelines
- VI. Other Business
- VII. Adjournment



Equine Drug Research Council

Tuesday Aug. 2, 2011

Location: Offices of the Kentucky Horse Racing Commission
4063 Iron Works Parkway, Building B
Lexington, Ky.
Time: 2 p.m. EDT

AGENDA

- I. Call to order and roll call
- II. Approve minutes of May 25, 2011 and June 8, 2011
- III. Vote to approve Research Proposals
- IV. Report from Race Day Medication Summit
- V. Amendments to 810 KAR 1:018; 811 KAR 1:090; 811 KAR 2:096 Medications, Testing Procedures, and Prohibited Practices
- VI. Amendments to 810 KAR 1:028; 811 KAR 1:095; 811 KAR 2:100 Disciplinary Measures and Penalties
- VII. 810 KAR 1:040 ; 811 KAR 1:093; 811 KAR 2:093. Drug and Medication Classification Schedules and Withdrawal Guidelines
- VIII. Request to release RFP for "Determination of Betamethasone in equine research samples"
- IX. Second Quarter Lab Report, Cost Comparison Analysis
- X. Drug Positives over time
- XI. Updated Injury Table
- XII. Introduction to research collaboration with UC Davis
- XIII. Other Business
- XIV. Adjournment